Although our study found some evidence that breast cancer risk was reduced among women with the highest lifetime use of non-aspirin, non-COXib NSAIDs, this finding was only significant when we categorized by pill-years of use and appears in association with tumors that are ER+/PR+/HER2-. Here, ERBB2 is linked to breast cancer.